These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 20536417)

  • 1. Macrocyclic inhibitors of hsp90.
    Johnson VA; Singh EK; Nazarova LA; Alexander LD; McAlpine SR
    Curr Top Med Chem; 2010; 10(14):1380-402. PubMed ID: 20536417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L; Wang L; You QD; Xu XL
    J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
    Hwang M; Moretti L; Lu B
    Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J; Eichner S; Zeilinger C; Kirschning A
    Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.
    Chan CT; Paulmurugan R; Gheysens OS; Kim J; Chiosis G; Gambhir SS
    Cancer Res; 2008 Jan; 68(1):216-26. PubMed ID: 18172314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
    Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Barzegar A; Akbarzadeh A; Shahabi A; Barekati-Mowahed M; Zarghami N
    Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of the HSP90 molecular chaperone: current status.
    Sharp S; Workman P
    Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
    Shen G; Wang M; Welch TR; Blagg BS
    J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
    Hall JA; Seedarala S; Rice N; Kopel L; Halaweish F; Blagg BS
    J Nat Prod; 2015 Apr; 78(4):873-9. PubMed ID: 25756299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Holmes JL; Sharp SY; Hobbs S; Workman P
    Cancer Res; 2008 Feb; 68(4):1188-97. PubMed ID: 18281495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
    Miyata Y
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
    Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
    Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90.
    Kang BH; Plescia J; Song HY; Meli M; Colombo G; Beebe K; Scroggins B; Neckers L; Altieri DC
    J Clin Invest; 2009 Mar; 119(3):454-64. PubMed ID: 19229106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.